



ASX ANNOUNCEMENT

2 March 2020

Change of Company Secretary and Registered Address

Medical technology company, HeraMED Limited (**ASX:HMD**) (**HeraMED** or **Company**) wishes to advise that with effect from 2 March 2020, Mr Jonathan Hart has been appointed Company Secretary.

Jonathan is currently a director of AppsVillage Australia Limited (ASX:APV) and company secretary for Mayur Resources Limited (ASX:MRL). He holds a Bachelor of Laws and Commerce and has provided corporate advisory services and held several board positions on various ASX listed companies over the years. His experience includes initial public offerings on ASX (AIM and JSE), reverse takeovers, due diligence investigations, general corporate and commercial drafting, public and private mergers and acquisitions, general corporate advice in relation to capital raisings, Corporations Act and ASX compliance.

The Board would like to take this opportunity to warmly thank the previous company secretary, Mr Stephen Buckley for his contribution to the Company since its listing on the ASX and to wish him well with his future endeavours.

The Company also advises that effective from today, the principal and registered office of the Company has changed to:

Suite 3, Level 10
23-25 Hunter Street
SYDNEY NSW 2000

Phone: +61 2 8379 2961

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972-52-6991188

E: David@hera-med.com

Company Secretary

Jonathan Hart

T: +61 2 8379 2961

E: jonathan@hera-med.com

About HeraMED Limited (ASX:HMD):

HeraMED Limited is an innovative medical technology company delivering smart pregnancy monitoring solutions for home and professional use. HeraMED provides peace of mind to expecting parents by solving challenges associated with the reliability and accessibility of pre-natal care. Through development and utilisation of end-to-end medical grade solutions, HeraMED overcomes the barriers of high-cost and shortage of fundamental services, enabling smart monitoring devices, cloud-based platform and AI capabilities

HeraMED is commercialising its smart medical grade ultrasound monitoring device, HeraBEAT. The device has passed multiple clinical trials and secured approval by key regulatory bodies including TGA (Australia), CE (Europe) and AMAR (Israel) for commercial sale.

The Company has partnerships with two leading medical organisations, the Mayo Clinic and TEVA Pharmaceutical Industries Inc. (NYSE: TEVA). HeraMED is diversifying its product range and services with the launch of SaaS services and cloud based monitoring systems.

HeraMED Limited ACN 626 295 314

T: +61 2 8379 2961 | **A:** Suite 3, Level 10, 23-25 Hunter Street SYDNEY NSW 2000